5-methyl-1-[4-(4-piperidin-1-ylbutoxy)phenyl]-1H-pyridin-2-one | 1415088-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-methyl-1-[4-(4-piperidin-1-ylbutoxy)phenyl]-1H-pyridin-2-one
• 英文别名: 5-methyl-1-(4-(4-(piperidin-1-yl)butoxy)phenyl)pyridin-2(1H)-one；5-Methyl-1-[4-(4-piperidin-1-ylbutoxy)phenyl]pyridin-2-one；5-methyl-1-[4-(4-piperidin-1-ylbutoxy)phenyl]pyridin-2-one
• CAS: 1415088-18-4
• 化学式: C₂₁H₂₈N₂O₂
• 分子量: 340.466
• InChiKey: QUJUKURTZCTMTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.79
• 重原子数：
  25.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  34.47
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  4-苄氧基溴苯 在 copper(l) iodide 、 5%-palladium/activated carbon 、 氢气 、 potassium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 154.0h， 生成 5-methyl-1-[4-(4-piperidin-1-ylbutoxy)phenyl]-1H-pyridin-2-one
  参考文献：
  名称：

  Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents

  摘要：

  A total of 24 pirfenidone derivatives were designed, synthesized and evaluated for their inhibitory activity against the human lung fibroblast cell line MRC-5. These compounds showed the remarkable proliferation inhibition against MRC-5 compared to pirfenidone as the positive control. The possible mechanism of this kind of derivatives as antifibrotic agents was explored. The molecular docking and p38 binding affinity assays demonstrated that the antifibrotic potential of the pirfenidone derivatives was possibly through the inhibition of p38 MAPK signaling pathway. The data from this study suggested that p38 might be a potential therapeutic target for the new generation antifibrotics. All the pirfenidone derivatives are reported here for the first time. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.038

文献信息

• SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION
  申请人：Creighton University

  公开号：US20170290819A1

  公开（公告）日：2017-10-12

  The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.

  本公开涉及吡非尼酮（5-甲基-1-苯基-2-(1H)-吡啶酮）及其衍生物和其药用盐，这些化合物的用途作为药物，并用于制造用于治疗或延缓肺动脉高压的药物。
• Small molecule therapies for pulmonary hypertension
  申请人：Creighton University

  公开号：US10420759B2

  公开（公告）日：2019-09-24

  The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.

  本公开涉及吡非尼酮（5-甲基-1-苯基-2-(1H)-吡啶酮）及其衍生物和其药学上可接受的盐、这些化合物作为药物的用途，以及用于制造治疗或延缓肺动脉高压发病或发展的药物。